Lytix Biopharma Enters Clinical Collaboration with Iovance Biotherapeutics
Norwegian clinical-stage immunoncology company, Lytix Biopharma, has entered into a clinical collaboration with US-based Iovance Biotherapeutics.
Norwegian clinical-stage immunoncology company, Lytix Biopharma, has entered into a clinical collaboration with US-based Iovance Biotherapeutics, it was unveiled in a Nov. 10, 2019 press release.
The companies will collaborate to evaluate Lytix’s first-in-class oncolytic peptide, LTX-315, in combination with Iovance’s autologous ready to infuse T-cell therapy. Under the terms of the non-exclusive agreement, both companies will retain ownership of their own assets.
“We are very excited about the collaboration with Iovance, and the combination of our technologies can be a potential new approach to T cell therapy for cancers,” said Øystein Rekdal, CEO of Lytix Biopharma. “This agreement affirms that we remain committed to the further development of LTX-315 as a single agent and in combination with other therapies.”
Source: Lytix Biopharma
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
